Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aclaris Therapeutics (ACRS) Shares Issued (2017 - 2024)

Historic Shares Issued for Aclaris Therapeutics (ACRS) over the last 7 years, with Q4 2024 value amounting to $74.9 million.

  • Aclaris Therapeutics' Shares Issued changed N/A to $74.9 million in Q4 2024 from the same period last year, while for Dec 2024 it was $74.9 million, marking a year-over-year change of. This contributed to the annual value of $74.9 million for FY2024, which is 18042.6% up from last year.
  • Latest data reveals that Aclaris Therapeutics reported Shares Issued of $74.9 million as of Q4 2024.
  • Over the past 5 years, Aclaris Therapeutics' Shares Issued peaked at $103.3 million during Q1 2021, and registered a low of -$101.9 million during Q2 2021.
  • For the 4-year period, Aclaris Therapeutics' Shares Issued averaged around $24.9 million, with its median value being $36.4 million (2022).
  • Per our database at Business Quant, Aclaris Therapeutics' Shares Issued skyrocketed by 41329200.0% in 2021 and then tumbled by 9996.42% in 2022.
  • Over the past 4 years, Aclaris Therapeutics' Shares Issued (Quarter) stood at $25000.0 in 2020, then tumbled by 407656.0% to -$101.9 million in 2021, then skyrocketed by 171.36% to $72.7 million in 2022, then rose by 2.99% to $74.9 million in 2024.
  • Its last three reported values are $74.9 million in Q4 2024, $72.7 million for Q2 2022, and $37000.0 during Q1 2022.